Skin-Specific Outcomes of Brepocitinib in Patients With Dermatomyositis: Secondary Analysis of a Phase 3 Randomized Clinical Trial.

Mangold AR, Haemel A, Shahriari N, Chong B, Fernandez AP, Fiorentino D, Pearson D, Sluzevich J, Onajin O, Rambhatla PV, Rashighi M, Hurabielle C, Fivenson D, Boh E, Paravar T, Crew A, Flowers RH, Taylor D, Subhardashani S, Culton D, Schadt C, Callen J, Lam C, Graham L, Hashemi K, Castillo R, Maderal A, Elman S, Shaw KS, Cascino MD, LaChance A, Min MS, Femia A, Vleugels RA, Werth VP

Open source

DOI: 10.1001/jamadermatol.2026.3199
Published: 2026 Aug 26
Container: JAMA dermatology
Publisher: Not recorded
Open access: unknown

Credibility signals

limited evidence Score 43/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredOpen access status: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1001/jamadermatol.2026.3199,
  title = {Skin-Specific Outcomes of Brepocitinib in Patients With Dermatomyositis: Secondary Analysis of a Phase 3 Randomized Clinical Trial.},
  author = {Mangold AR and Haemel A and Shahriari N and Chong B and Fernandez AP and Fiorentino D and Pearson D and Sluzevich J and Onajin O and Rambhatla PV and Rashighi M and Hurabielle C and Fivenson D and Boh E and Paravar T and Crew A and Flowers RH and Taylor D and Subhardashani S and Culton D and Schadt C and Callen J and Lam C and Graham L and Hashemi K and Castillo R and Maderal A and Elman S and Shaw KS and Cascino MD and LaChance A and Min MS and Femia A and Vleugels RA and Werth VP},
  year = {2026},
  journal = {JAMA dermatology},
  doi = {10.1001/jamadermatol.2026.3199},
  url = {https://doi.org/10.1001/jamadermatol.2026.3199}
}

RIS

TY  - JOUR
TI  - Skin-Specific Outcomes of Brepocitinib in Patients With Dermatomyositis: Secondary Analysis of a Phase 3 Randomized Clinical Trial.
AU  - Mangold AR
AU  - Haemel A
AU  - Shahriari N
AU  - Chong B
AU  - Fernandez AP
AU  - Fiorentino D
AU  - Pearson D
AU  - Sluzevich J
AU  - Onajin O
AU  - Rambhatla PV
AU  - Rashighi M
AU  - Hurabielle C
AU  - Fivenson D
AU  - Boh E
AU  - Paravar T
AU  - Crew A
AU  - Flowers RH
AU  - Taylor D
AU  - Subhardashani S
AU  - Culton D
AU  - Schadt C
AU  - Callen J
AU  - Lam C
AU  - Graham L
AU  - Hashemi K
AU  - Castillo R
AU  - Maderal A
AU  - Elman S
AU  - Shaw KS
AU  - Cascino MD
AU  - LaChance A
AU  - Min MS
AU  - Femia A
AU  - Vleugels RA
AU  - Werth VP
PY  - 2026
JO  - JAMA dermatology
DO  - 10.1001/jamadermatol.2026.3199
UR  - https://doi.org/10.1001/jamadermatol.2026.3199
ER  -

APA

AR, M., A, H., N, S., B, C., AP, F., D, F., D, P., J, S., O, O., PV, R., M, R., C, H., D, F., E, B., T, P., A, C., RH, F., D, T., S, S., D, C., C, S., J, C., C, L., L, G., K, H., R, C., A, M., S, E., KS, S., MD, C., A, L., MS, M., A, F., RA, V., & VP, W. (2026). Skin-Specific Outcomes of Brepocitinib in Patients With Dermatomyositis: Secondary Analysis of a Phase 3 Randomized Clinical Trial.. JAMA dermatology. https://doi.org/10.1001/jamadermatol.2026.3199

Source records

pubmed · retrieved 2026-09-25T09:05:09.023Z